Aytu BioPharma (NASDAQ:AYTU) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Aytu BioPharma (NASDAQ:AYTU) from a strong sell rating to a hold rating in a research report released on Monday morning,Zacks.com reports.

Several other analysts have also recently issued reports on the company. Ascendiant Capital Markets upped their price objective on Aytu BioPharma from $12.50 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Friday, January 9th. Finally, Wall Street Zen upgraded shares of Aytu BioPharma to a “hold” rating in a report on Saturday, February 7th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Aytu BioPharma currently has a consensus rating of “Hold” and an average target price of $9.33.

Aytu BioPharma Price Performance

Shares of NASDAQ:AYTU opened at $2.64 on Monday. The firm has a market cap of $28.33 million, a price-to-earnings ratio of -0.69 and a beta of 0.35. The firm has a fifty day moving average price of $2.52 and a 200 day moving average price of $2.33. Aytu BioPharma has a fifty-two week low of $0.95 and a fifty-two week high of $3.07. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.03 and a current ratio of 1.16.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.79). Aytu BioPharma had a negative net margin of 39.02% and a negative return on equity of 28.22%. The company had revenue of $15.17 million during the quarter, compared to the consensus estimate of $12.17 million.

Hedge Funds Weigh In On Aytu BioPharma

Several hedge funds have recently added to or reduced their stakes in the company. Stonepine Capital Management LLC lifted its stake in Aytu BioPharma by 75.3% in the second quarter. Stonepine Capital Management LLC now owns 812,676 shares of the company’s stock worth $1,772,000 after purchasing an additional 348,955 shares during the last quarter. AWM Investment Company Inc. purchased a new stake in shares of Aytu BioPharma in the second quarter worth approximately $1,351,000. Persistent Asset Partners Ltd bought a new stake in shares of Aytu BioPharma during the 3rd quarter worth approximately $117,000. Dimensional Fund Advisors LP purchased a new position in Aytu BioPharma during the 3rd quarter valued at $58,000. Finally, Two Sigma Investments LP boosted its holdings in Aytu BioPharma by 96.2% during the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock valued at $129,000 after acquiring an additional 33,701 shares during the period. 33.49% of the stock is currently owned by institutional investors.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.